One subgroup of MAPKs, p44/42 MAPK (ERK1/2), is an important target in the diagnosis and treatment of cancer and has been reported to be required for the upregulation of p21WAF/CIP1 that results in cell-cycle arrest [46]–[48]. This evidence concerns the gene MAPK3 and cancer.